Nosocomial Candida krusei fungemia in cancer patients: report of 10 cases and review

The risk factors, therapy and outcome of ten cases of fungemia due to Candida krusei, appearing during the last 10 years in a single national cancer institution, are analyzed. Univariate analyses did not find any specific risk factors in comparison to 51 Candida albicans fungemias appearing at the s...

Full description

Saved in:
Bibliographic Details
Published inJournal of chemotherapy (Florence) Vol. 11; no. 2; p. 131
Main Authors Krcmery, Jr, V, Spanik, S, Kunova, A, Trupl, J, Grausova, S, Krupova, I, Mateicka, F, Pichnova, E, Grey, E, Sabo, A
Format Journal Article
LanguageEnglish
Published England 01.04.1999
Subjects
Adult
Aged
Amphotericin B
Antifungal Agents - therapeutic use
Candida - pathogenicity
Candidiasis - etiology
Candidiasis - mortality
Candidiasis - therapy
Cross Infection - etiology
Cross Infection - therapy
Female
Fluconazole
Fungemia - etiology
Fungemia - mortality
Fungemia - therapy
Humans
Incidence
Male
Middle Aged
Neoplasms - complications
Neoplasms - microbiology
Risk Assessment
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:The risk factors, therapy and outcome of ten cases of fungemia due to Candida krusei, appearing during the last 10 years in a single national cancer institution, are analyzed. Univariate analyses did not find any specific risk factors in comparison to 51 Candida albicans fungemias appearing at the same institution and with a similar antibiotic policy. Association with prior fluconazole prophylaxis was not confirmed because only one case appeared in a patient previously treated with fluconazole. However, attributable and crude mortality due to C. krusei fungemias was higher than for C. albicans fungemia. The authors review 172 C. krusei fungemias published within the last 10 years to compare with the incidence, therapy and outcome of C. krusei fungemia from our cancer institute.
ISSN:1120-009X
DOI:10.1179/joc.1999.11.2.131